News | Latest Breaking News Stories & Headlines

Perrigo says the tax bill was a 'breach of its legitimate expectations'

Pharmaceutical firm contests €1.6 billion tax bill

The Commercial Court has begun hearing arguments in a judicial review of a decision by Revenue to issue a tax bill of €1.64 billion to pharmaceutical company Perrigo two years ago.

Courts • 04 Jun 20

The action arises from an assessment for 2013 which altered the amount of tax Revenue claims is due from the company

Perrigo seeks judicial review of €1.6bn tax ruling

An Irish registered pharmaceutical company has been granted permission by the High Court to bring a judicial review application aimed at overturning a €1.6 billion tax demand by Revenue.

Business • 25 Feb 19

Under the terms of the deal, Perrigo and Elan have been combined under a new company incorporated in Ireland

Perrigo completes Elan deal

Perrigo has completed the acquisition of Elan in a deal valued at about $8.6 billion.

Business • 19 Dec 13

Elan urges shareholders to take no action on latest bid from Royalty Pharma

Royalty Pharma raises Elan bid

Royalty Pharma last night raised its hostile bid for Elan to $12.50 per share.

Business • 21 May 13

Royalty Pharma's takeover bid for Elan enters third month

Royalty Pharma submits Elan offer

Royalty Pharma today formally submitted its $11.25 per share bid for Elan to the company's shareholders.

Business • 02 May 13

Elan says global Tysabri sales rose by 14% in first quarter of 2013

Elan says it has $2 billion in cash for deals

Elan has reported a net loss from continuing operations of €72.8m for the three months to the end of March.

Business • 24 Apr 13

Elan says Royalty Pharma offer undervalues company

Elan board rejects Royalty Pharma bid

The board of Elan has unanimously rejected a formal bid from Royalty Pharma, saying the offer of $11.25 a share grossly undervalues the company.

Business • 22 Apr 13

Royalty Pharma may offer Elan shareholders more if MS drug hits sales milestones

Elan shareholders vote in favour of share buyback

Elan shareholders have voted overwhelmingly in favour of a $1 billion share buyback scheme announced in February.

Business • 12 Apr 13

Elan completes Tysabri sale deal with Biogen Idec

Elan completes sale of Tysabri stake to Biogen

Elan has closed the sale of its 50% stake in multiple sclerosis drug Tysabri.

Business • 03 Apr 13

Royalty Pharma set to meet with Elan shareholders

Royalty Pharma ready to move quickly on Elan bid

Royalty Pharma said today that it was standing by its offer to acquire Elan, which has rejected the approach.

Business • 06 Mar 13

Elan says "unique" cash dividend policy would give shareholders the right to enjoy unlimited participation in the upside from Tysabri sales

Elan offers Tysabri dividend after Royalty bid

Elan has said it will give shareholders 20% of the royalty rights for multiple sclerosis drug Tysabri.

Business • 04 Mar 13

''Any credible proposal which may be made by Royalty Pharma or any other party will of course be considered'', says Elan

Royalty Pharma offer highly opportunistic - Elan

Elan shares are higher in Dublin trade today after the news that Royalty Pharma had made an indicative proposal to acquire the company.

Business • 25 Feb 13

Elan to use almost a third of the $3.25 billion proceeds from Tysabri deal to buy back shares

Elan to use Tysabri proceeds to buy back shares

Pharmaceutical company Elan said it will return $1 billion of the proceeds from selling its stake in the multiple sclerosis treatment Tysabri to shareholders.

Business • 22 Feb 13

Elan restructures Tysabri deal with Biogen Idec

Elan has announced a restructuring of its MS drug Tysabri collaboration with Biogen Idec, which will see Biogen getting full ownership and control of multiple sclerosis drug Tysabri.

Business • 06 Feb 13

Biogen profits slip on tax accounting error

Biogen Idec's fourth-quarter net profit fell slightly due to a tax accounting error.

Business • 28 Jan 13

Elan and Biogen Idec hope Tysabri would be used more widely and at earlier stage of treatment for MS

Elan and Biogen eye MS drug sales boost

Elan and Biogen Idec have filed for approval to sell their drug Tysabri as a first-line treatment for multiple sclerosis.

Business • 16 Jan 13

Elan's Q3 revenues up 10%, but losses mount

Elan has reported third quarter revenues of $306.6m for the three months to the end of September.

Business • 24 Oct 12

Elan to spin off Neotope Biosciences unit

The board of Elan has approved the spin-off of its discovery science and Neotope Biosciences from the company, in a move which makes Elan immediately profitable.

Business • 13 Aug 12

Tysabri